Results 11 to 20 of about 117,203 (208)

Toward replacing late gadolinium enhancement with artificial intelligence virtual native enhancement for gadolinium-free cardiovascular magnetic resonance tissue characterization in hypertrophic cardiomyopathy [PDF]

, 2021
Background: Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) imaging is the gold standard for noninvasive myocardial tissue characterization but requires intravenous contrast agent administration.
Qiang Zhang, Iulia A. Popescu, Mayooran Shanmuganathan, Suleyman D. Polat, Ahmet Barutcu, Stefan K. Piechnik, Michael Jerosch-Herold, Vanessa M. Ferreira, Matthew K. Burrage, Hugh C. Watkins, Chrysovalantou Nikolaidou, Rebecca Mills, Evan Hann, Michael Salerno, Elena Lukaschuk, Raymond Y. Kwong, Konrad Werys, Stefan Neubauer, Christopher M. Kramer   +18 more
core   +1 more source

Ventricular arrhythmias complicating hypertrophic cardiomyopathy

, 2012
Hypertrophic cardiomyopathy is the most common genetic cardiovascular disorder and the leading cause of sudden cardiac death in the young. This article reviews the ventricular arrhythmias associated with hypertrophic cardiomyopathy, the difficulties in ...
Venetucci, Luigi, Sankaranarayanan, Rajiv, Hutchings, David; id_orcid   +2 more
core   +5 more sources

Hypertrophic cardiomyopathy and ultra-endurance running - two incompatible entities? [PDF]

, 2011
Regular and prolonged exercise is associated with increased left ventricular wall thickness that can overlap with hypertrophic cardiomyopathy (HCM). Differentiating physiological from pathological hypertrophy has important implications, since HCM is the ...
Sanjay K Prasad, Papadakis, M, Sharma Sanjay, Prasad, Sanjay K., Chandra, N, Prasad, SK, O'Hanlon, Rory, O'Hanlon Rory, Papadakis, Michael, O'Hanlon, R, Chandra, Navin, Prasad Sanjay K, Michael Papadakis, Sharma, Sanjay, Chandra Navin, Papadakis Michael, Rory O'Hanlon, Wilson, MG, Wilson, Mathew G., Wilson Mathew G, Sanjay Sharma, Sharma, S, Mathew G Wilson, Navin Chandra   +23 more
core   +1 more source

Quality first in obstructive hypertrophic cardiomyopathy

, 2021
Increasing clinician awareness, earlier diagnosis, and implantable cardioverter-defibrillators have allowed hypertrophic cardiomyopathy to transition from being a relatively common cause of sudden death in young people to a chronic disease affecting ...
Prasad, Sandhir B, Atherton, John J, Sandhir B Prasad, John J Atherton   +3 more
core   +1 more source

Hypertrophic Cardiomyopathy

, 2023
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy resulting from a mutation in one of several cardiac sarcomeric proteins [...
Deya Alkhatib, Issa Pour-Ghaz, Sakiru Isa, Neeraja Yedlapati, Asra K. Butt, Ifeoma Ugonabo, John Lynn Jefferies, Omar Al-Taweel, Pour-Ghaz, Issa, Ugonabo, Ifeoma, Jefferies, John Lynn, Yedlapati, Neeraja, Isa, Sakiru, Butt, Asra K., Alkhatib, Deya, Al-Taweel, Omar   +15 more
core   +1 more source

Availability and Utilization of Automated External Defibrillators in New York State Schools

Frontiers in Pediatrics, 2021
Background: Use of automated external defibrillators (AEDs) in out-of-hospital cardiac arrests (OHCAs) improve survival. Professional health organizations recommend that AEDs be available in crowded places, including schools but currently only 18 US ...
Milla Arabadjian, Milla Arabadjian, Stephanie Serrato, Mark V. Sherrid   +3 more
doaj   +1 more source

Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy

Scientific Reports, 2021
Hypertrophic cardiomyopathy (HCM) is characterized by phenotypic heterogeneity. We investigated the molecular basis of the cardiac phenotype in two mouse models at established disease stage (mouse-HCM), and human myectomy tissue (human-HCM).
Styliani Vakrou, Yamin Liu, Li Zhu, Gabriela V. Greenland, Bahadir Simsek, Virginia B. Hebl, Yufan Guan, Kirubel Woldemichael, Conover C. Talbot, Miguel A. Aon, Ryuya Fukunaga, M. Roselle Abraham   +11 more
doaj   +1 more source

Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundThe subcutaneous implantable cardioverter defibrillator (S‐ICD) has been developed to avert risks associated with transvenous defibrillator leads. The technology is attractive for younger patients, such as those with hypertrophic cardiomyopathy
Jonathan Weinstock, Yousef H. Bader, Martin S. Maron, Ethan J. Rowin, Mark S. Link   +4 more
doaj   +1 more source

COVID-19 in Adults With Hypertrophic Cardiomyopathy

Frontiers in Cardiovascular Medicine, 2021
Background: Individuals with cardiovascular disease are considered high risk for severe COVID-19. However, the clinical impact of COVID-19 in patients with hypertrophic cardiomyopathy (HCM) is unknown.
Milla E. Arabadjian, Maria C. Reuter, Alexandra Stepanovic, Mark V. Sherrid, Daniele Massera   +4 more
doaj   +1 more source

Weight loss in hypertrophic cardiomyopathy: A clinical case series

International Journal of Cardiology. Cardiovascular Risk and Prevention, 2023
Background: Obesity is prevalent among patients with hypertrophic cardiomyopathy (HCM). Obese HCM patients have greater wall thickness, LV mass, worse hemodynamic function and NYHA class. Weight loss may favorably influence the HCM phenotype.
Maria C. Reuter, Daniele Massera, Leon Axel, Larry A. Latson, Jonathan M. Goldstein, Alexandra Stepanovic, Mark V. Sherrid   +6 more
doaj   +1 more source